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Brugada syndrome is a clinical entity characterized by type-1 (coved) ST-segment elevation in the right
precordial electrocardiographic leads (V1–V3) and an aborted sudden cardiac death due to ventricular
ﬁbrillation (VF) in the absence of structural heart disease. Since 1992, when Brugada and Brugada
reported the ﬁrst case, numerous studies across the world have characterized the clinical, electro-
cardiographic, electrophysiologic, and prognostic features of Brugada syndrome. Several multicenter
studies also suggested the natural history and proposed the risk stratiﬁcation for subsequent cardiac
events. In this review article, the clinical features of Brugada syndrome will be updated.
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Brugada syndrome is characterized by speciﬁc ST-segment
changes in the right precordial electrocardiographic leads, known
as the type-1 or coved-type Brugada electrocardiogram (ECG). In
addition, Brugada syndrome is associated with a high risk ofrt Rhythm Society. Published by E
cine, Division of Cardiology,
okyo 113-8603, Japan.sudden cardiac death due to ventricular ﬁbrillation (VF) without
structural heart diseases. Since Brugada and Brugada ﬁrst
described 8 patients with a history of aborted sudden cardiac
death due to VF and type-1 ECG in 1992, Brugada syndrome has
become a distinct clinical entity [1–8].2. Epidemiology
The worldwide prevalence of Brugada syndrome [8] is esti-
mated to be 1 in 10,000, but it is much higher in Asian andlsevier B.V. All rights reserved.
Fig. 1. (A) Spontaneous type-1 (coved) ST-segment elevation (arrow). (B) Unmasking of ST-segment elevation by a class IC sodium channel blocker, pilsicainide. Under
baseline condition, type-2 (saddle-back) ST-segment elevation is recorded in lead V2 (left, arrow). Pilsicainide injection (30 mg) unmasks type-1 electrocardiogram (ECG)
in lead V2 (right, arrow). (C) Unmasking of type-1 ECG by recordings of right precordial (V1–V2) leads at third and second intercostal spaces. No signiﬁcant ST-segment
elevation is observed in leads V1 and V2 of the standard 12-lead ECG (fourth intercostal space) (left, arrow), while type-2 (middle, arrow) and type-1 (right, arrow) ST-
segment elevation are unmasked in leads V1 and V2 recorded from the third and second intercostal spaces, respectively.
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Thailand, reaching 5–10 in 10,000, while it is much lower in some
Eastern European countries like Denmark, with an estimated
prevalence of 1.1 in 100,000. Brugada syndrome, also known as
pokkuri (Japan), bangungot (the Philippines), and lai tai (Thai-
land), seems to be the most common cause of natural death in
Asian men younger than 50 years. The reason for this higher
prevalence in Asia may be in part related to an Asian-speciﬁc
sequence in the promoter region of SCN5A [9].
Brugada syndrome usually manifests during adulthood, with a
mean age of sudden death of 41715 years; however, cases in
children are rare [8]. A family history of unexplained sudden
death is present in 20–40% of cases in Western countries and
15–20% of cases in Japan [5,8,10,11].
Male predominance in patients with Brugada syndrome is also
well known. Since all of the mutations identiﬁed in patients with
Brugada syndrome display an autosomal dominant mode of
transmission, men and women are genetically expected to equally
inherit the defective gene. However, the clinical phenotype is 8–
10 times more prevalent in men than in women [8]. Experimental
studies in dogs have suggested that the presence of a more
prominent transient outward current (Ito) in males may contri-
bute to the male predominance of the syndrome [12]. Some
clinical studies have suggested that higher testosterone levels in
men than in women may also have a signiﬁcant role in the male
predominance [13].
Episodes of VF occur more frequently at night or during sleep
(2000–0800) than during the daytime as a form of sudden
unexplained nocturnal death, syncope, or agonal respiration in
approximately 70–80% of patients with Brugada syndrome
[8,14,15]. Some authors speculate that this circadian pattern is
related to increased vagal tone [16]. Our data detected by
implantable cardioverter deﬁbrillator (ICD) have shown that
about half of the VF episodes are preceded by ventricular
premature complex (VPC) with a similar morphology to initiatingVPC of VF [15]. Atrial ﬁbrillation is associated with 10–20% of
Brugada cases in Western countries and 20–30% of Brugada cases
in Japan [17]. The association of atrioventricular nodal reentrant
tachycardia or Wolff-Parkinson-White (WPW) syndrome has also
been reported.[18]3. Electrocardiographic characteristics
The ﬁst Brugada Consensus Report in 2002 suggested 3 types
of ST-segment elevation patterns in the right precordial leads of
the ECG (Fig. 1) [6]. Type-1 or coved-type ST-segment elevation is
characterized by a J-point elevation of Z2 mm (0.2 mV) followed
by a negative or isoelectric T-wave (Fig. 1A). Type-2 ST-segment
elevation shows a saddleback appearance with a J-point elevation
of Z2 mm followed by a trough displaying a Z1-mm ST eleva-
tion with either a positive or biphasic T-wave (Fig. 1B). Type-3 ST-
segment elevation has a saddleback appearance with a J-point
elevation of o1 mm. The morphology and level of the ST-
segment elevation are often accentuated; however, the type-1
or coved-type Brugada ECG is more frequently recognized just
before and after episodes of VF [19,20] and is linked to a higher
incidence of VF and sudden cardiac death [21]. Although the
original report by Brugada and Brugada described the presence of
right bundle branch block (RBBB), the RBBB was revealed to be
nonessential for the diagnosis of Brugada syndrome [6]. Mild
depolarization abnormalities, such as widening of the P wave and
QRS duration, and prolongation of the PQ interval are observed in
patients with Brugada syndrome, more often in those with SCN5A
mutations than in those without SCN5A mutations [22].
4. Diagnostic criteria
Brugada syndrome is deﬁnitively diagnosed when a type-1 ST-
segment elevation is observed in at least 1 right precordial lead
Table 1
Acquired form of Brugada Syndrome.
1. Antiarrhythmic drugs
(1) Sodium channel blockers
Class IC drugs (Flecainide, Pilsicainide, Propafenone)
Class IA drugs (Ajmaline, Procainamide, Disopyramide,
Cibenzoline)
(2) Calcium channel blockers
Verapamil
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the second intercostal space) (Fig. 1C) [24,25], in the presence or
absence of a sodium channel blocking agent (ajmaline, ﬂecainide,
pilsicainide, or procainamide) (Fig. 1B). Although the diagnostic
criteria from the Second Consensus Report in 2005 require a type-
1 ECG in at least 2 right precordial leads (V1–V3) for the deﬁnitive
diagnosis, several clinical studies thereafter have indicated that a
type-1 ECG recorded in at least 1 right precordial lead (V1 and V2)
was enough for deﬁnitively diagnosing Brugada syndrome [26].(3) b blockers
Propranolol, etc.
2. Antianginal drugs
(1) Calcium channel blockers
Nifedipine, Diltiazem, etc.
(2) Nitrate
Isosorbide dinitrate, Nitroglycerine, etc.
(3) Potassium channel openers
Nicorandil, etc.
3. Psychotropic drugs
(1) Tricyclic antidepressants
Amitriptyline, Nortriptyline, Desipramine,
Clomipramine, dosulepin, etc.
(2) Tetracyclic antidepressants
Maprotiline, etc.
(3) Phenothiazine
Perphenazine, Cyamemazine, etc.
(4) Benzodiazepine5. Differential diagnosis
Diseases and conditions that can lead to Brugada-like ECG
abnormality should be differentially diagnosed. These diseases
and conditions include atypical RBBB, left ventricular hypertro-
phy, early repolarization, acute pericarditis, acute myocardial
ischemia or infarction, pulmonary embolism, Prinzmetal angina,
dissecting aortic aneurysm, various central and autonomic ner-
vous system abnormalities, Duchenne muscular dystrophy, thia-
min deﬁciency, arrhythmogenic right ventricular cardiomyopathy
(ARVC), pectus excavatum, and mechanical compression of the
right ventricular outﬂow tract as occurs in mediastinal tumor or
hemopericardium [8,23,27].Clonazepam, Alprazolam, Lorazepam, etc.
(5) Selective serotonin reuptake inhibitors
Fluoxetine, Paroxetine, etc.
(6) Other antidepressants
Trazodone, Risperidone, etc.
4. Other drugs
(1) Histaminic H1 receptor antagonists
Dimenhydrinate, etc.
(2) Anti-inﬂammatory drugs
Mesalazine, etc.
(3) Psychoactive recreational drugs
Cocaine, Cannabis
(4) Antipsychotic drugs
Lithium, Thioridazine
(5) Local anesthetics
Bupivacaine
(6) Short-acting hypnotic agents
Propofol
5. Hypertestosteronemia
6. Low visceral fat
7. Myocardial ischemia
(1) Right ventricular infarction/ischemia
(2) Vasospastic angina
8. Myocarditis, Pericarditis
(1) Acute myocarditis
(2) Chronic myocarditis
(3) Acute Pericarditis
9. Temperature
(1) Hyperthermia (Febrile state)
(2) Hypothermia
10. Electrolyte abnormalities
(1) Hyperkalemia
(2) Hypokalemia
(3) Hypercalcemia6. Acquired form of Brugada syndrome
The ST segment in the right precordial leads is well known to
be modulated by several drugs (mainly antiarrhythmic drugs) and
autonomic agents [20]. Class IC antiarrhythmic drugs amplify or
unmask the ST-segment elevation most effectively as a result of
their strong effect of blocking fast sodium current (INa) [28,29]
and are used as a diagnostic tool in latent Brugada syndrome.
Many drugs and conditions that increase outward currents (e.g.,
Ito, adenosine triphosphate sensitive potassium current [IK-ATP]) or
decrease inward currents (e.g., L-type calcium current [ICa-L], fast
INa) at the end of phase 1 of the action potential can accentuate or
unmask ST-segment elevation, similar to that found in Brugada
syndrome (Table 1). This is described as an ‘‘acquired’’ form of
Brugada syndrome similar to the ‘‘acquired’’ form of long QT
syndrome. Several drugs and conditions other than class IC
antiarrhythmic drugs have been reported to produce an acquired
form of Brugada syndrome. These drugs and conditions include
antianginal drugs; psychotropic drugs; histaminic H1 receptor
antagonists; anti-inﬂammatory drugs; psychoactive recreational
drugs; antipsychotic drugs; local anesthetics; short-acting hyp-
notic agents; hypertestosteronemia; hyperthermia (febrile state);
hypothermia; and electrolyte abnormalities, such as hyperkale-
mia, hypokalemia, hypercalcemia, or hyponatremia [27,30,31].
These drugs and conditions unmask Brugada phenotype mainly
by depressing fast INa and ICa-L. (See also www.brugadadrugs.org.)(4) Hyponatremia
11. Meal, Increased insulin level
12. Polymorphisms in SCN5A7. Clinical features and natural history
Several symptoms related to Brugada syndrome include (1) VF
or aborted sudden cardiac death (more frequent at night than
during the day), (2) syncope, (3) nocturnal agonal respiration,
(4) palpitations, and (5) chest discomfort. These symptoms are
documented frequently at rest, during sleep, or under other
vagotonic conditions, but rarely during exercise.
Identiﬁcation of patients at high risk for sudden cardiac death
due to VF is important for managing patients with Brugada
syndrome [5,7,10,11,32,33]. Brugada et al. reported that patients
with type-1 Brugada ECG initially presenting with aborted sudden
cardiac death or VF are at the highest risk for a recurrence (69% at54754 months of follow up) [7]. Patients presenting with
syncope and a type-1 ECG are also reported to have a high
recurrence rate (19% at 26736 months of follow-up). Even in
asymptomatic Brugada patients, a relatively high cardiac-event
rate (8%) was reported in their registry. In contrast to the Brugada
registry, a recent European registry found a lower incidence of
subsequent arrhythmic events. The FINGER study by Probst et al.
reported that the annual rates of subsequent or new arrhythmic
events in patients with prior aborted sudden cardiac death,
patients with prior syncope, and asymptomatic patients are
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endorsed by the Japanese Ministry of Health, Labour and Welfare
also demonstrated a lower rate of arrhythmic events than those of
the Brugada registry. The annual rate of arrhythmic events in
probands with type-1 Brugada ECG was 10.2% in the VF group,
0.6% in the syncope group, and 0.5% in the asymptomatic group
[33]. The discrepancy in clinical outcomes of patients between the
Brugada registry and the other 2 registries is most likely due to
inclusion of particular families with a very severe form of the
disease in the Brugada registry.
It is generally agreed that a previous history of aborted cardiac
arrest, syncope, presence of a spontaneous type-1 ECG, and male
gender are signiﬁcant predictors of further arrhythmic events
[5,7,10,11,32,33].8. Risk stratiﬁcation
Considering the natural history of Brugada patients, there is
little controversy on the indication of ICD in Brugada patients
with a history of aborted cardiac arrest or those with a history of
syncope likely caused by VF as class I or class IIa ICD indication.
The more important goal is to stratify risk in asymptomatic
patients with Brugada syndrome displaying a typical type-1
ECG. Several clinical examinations have been useful in supporting
the diagnosis of Brugada syndrome and stratifying high-risk
patients.9. Exercise testing
Some clinical studies have reported the augmentation of ST-
segment elevation and/or unmasking of type-1 ECG in the right
precordial leads at early recovery periods after exercise in some
patients with Brugada syndrome (Fig. 2) [34,35]. We recentlyPre 
exercise
Peak 
exercise
V
2
0.32 mV 0.18  mV
V2
0.72  mV0.40 mV
V2
0.12 mV0.22 mV
Fig. 2. Responses of ST-segment elevation in lead V2 during exercise testing in 3 patie
exercise but re-ascended at the early recovery phase (3 min) resulting in typical type-1
at peak exercise and remained augmented at the early recovery phase. (C). The ST-se
baseline at recovery phase. ST-segment amplitudes are shown as numeric values.investigated the prevalence and the clinical signiﬁcance of the
augmentation of ST-segment elevation at the early recovery
phase for risk stratiﬁcation in Brugada patients [35]. Treadmill
exercise testing was conducted in 93 patients with Brugada
syndrome (22 documented VF, 35 syncope alone, and 36 asymp-
tomatic) and 102 healthy control subjects. Augmentation of ST-
segment elevation Z0.05 mV in leads V1 through V3 compared
with baseline was observed at early recovery (1–4 min at recov-
ery) in 34 Brugada patients (37%) (Fig. 2A and B) but not in the
remaining 59 Brugada patients (63%) (Fig. 2C) or 102 control
subjects. The ST-segment elevation was usually ameliorated at
peak exercise (Fig. 2A), but it was augmented even at peak
exercise in some patients (Fig. 2B). The Brugada patients asso-
ciated with the ST-segment augmentation at the early recovery
phase had a greater risk of subsequent VF than those without (15/
34 [44%] vs. 10/59 [17%], P¼0.004) during 76738 months of
follow up. Multivariate Cox regression analysis showed that
augmentation of ST-segment elevation at the early recovery
phase was a signiﬁcant and independent predictor for cardiac
events (P¼0.007), especially in patients with a history of syncope
alone (6/12 [50%] vs. 3/23 [13%]) and in asymptomatic patients
(3/15 [20%] vs. 0/21 [0%]). Thus, augmentation of ST-segment
elevation at the early recovery phase during exercise testing was
speciﬁc in patients with Brugada syndrome and can be a predictor
of poor prognosis, especially in patients with syncope alone and
in asymptomatic patients.10. Signal-averaged ECG
Frequency of late potentials (LP) in the signal-averaged ECG
has been reported to be higher in patients with Brugada syn-
drome than in control subjects. In a single-center study, Ikeda
et al. reported a sensitivity of 89%, speciﬁcity of 50%, positiveRecovery 
3 min
Recovery 
6 min
0.70  mV 0.48 mV
1 mV
0.80  m V 0.54 m V
0.20 mV0.14 mV
1 s
nts with Brugada syndrome. (A). The ST-segment elevation was decreased at peak
ST-segment elevation. (B). In some cases, the ST-segment elevation was augmented
gment elevation was decreased at peak exercise and gradually recovered to the
W. Shimizu / Journal of Arrhythmia 29 (2013) 65–70 69predictive value of 70%, and negative predictive value of 77% for
LP for risk stratiﬁcation of life-threatening events [36].11. Fragmented QRS
Morita and colleagues reported that fragmented QRS recorded
in the standard 12-lead ECGs (with 0- to 150-Hz ﬁlters) was more
often observed in Brugada patients with VF episodes than in those
with syncope or in asymptomatic patients [37]. They also
reported that patients who had fragmented QRS frequently
experienced recurrence of syncope due to VF within 4 years of
the ﬁrst episode of syncope or VF. More recently, in the PRELUDE
study, Priori et al. reported that fragmented QRS was an inde-
pendent predictor for arrhythmic events in Brugada patients
without a history of VF [38].12. Atrial ﬁbrillation
Spontaneous atrial ﬁbrillation (AF) has been reported to
appear in 10–53% of patients with Brugada syndrome and to be
associated with a higher incidence of syncopal episodes (60.0% vs.
22.2%, Po0.03) and documented VF (40.0% vs. 14.3%, Po0.05)
[39,40].13. Programmed electrical stimulation
The usefulness of programmed electrical stimulation (PES) to
stratify risk of subsequent arrhythmic events has long been
controversial between the Brugada registry and other registries
[5,7,10,11,32,33]. To ﬁll this gap, Priori organized a multicenter
prospective registry (PRELUDE study) with a uniform protocol in
patients with Brugada syndrome without a history of VF [38].
They suggested that arrhythmia inducibility during PES was not a
predictor of subsequent events during follow-up but that a
ventricular effective refractory period o200 ms was an indepen-
dent predictor for arrhythmic events. Makimoto et al. recently
reported a signiﬁcance of the number of extrastimuli at PES as a
predictor of arrhythmic events in patients with type-1 Brugada
ECG [41]. Multivariate Cox regression demonstrated that the
induction of VF with up to double extrastimuli was an indepen-
dent predictor. Therefore, they suggested that up to double
extrastimuli were adequate at PES to stratify risk in patients with
Brugada syndrome.14. Cardiac imaging
Several cardiac imaging techniques, such as exercise radio-
nuclide imaging (RI), computed tomography (CT), magnetic reso-
nance imaging (MRI), or echography, are required to prove the
absence of structural heart disease, including myocardial ische-
mia and ARVC.15. Head-up tilt testing
Head-up tilt (HUT) testing is recommended to judge an
episode of syncope to be likely caused by VF by excluding
neurally mediated syncope (NMS). However, NMS may coexist
with Brugada syndrome [42]. We conducted HUT testing in 46
patients with type-1 Brugada ECG, 20 healthy control subjects,
and 15 patients with suspected NMS [43]. HUT testing was
positive in 35% of Brugada patients (16/46), 10% of control
subjects (2/20), and 67% of suspected NMS patients (10/15). TheHUT-positive rate was signiﬁcantly higher in Brugada patients
with VF (7/14; 50%) than that in control subjects (10%) (Po0.05).
Augmentation of ST-segment amplitude (Z0.05 mV) in leads V1
through V3 was observed in 69% of the HUT-positive Brugada
patients (11/16) during vasovagal responses and was associated
with augmentation of parasympathetic tone following sympa-
thetic withdrawal, which was evaluated by the heart rate varia-
bility. These data suggested that some Brugada patients have an
impaired balance of the autonomic nervous system, which may
relate to their syncopal episodes.Conﬂict of interest
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